Gyre Therapeutics (GYRE) said its Hydronidone compound to treat liver fibrosis in patients with chronic hepatitis B met the primary endpoint in the phase 3 trial in China.
The 52-week trial revealed that almost 53% of patients receiving Hydronidone achieved 1-stage regression in liver fibrosis versus placebo, Gyre said Thursday in a statement.
The drug was well tolerated with no discontinuations due to adverse events, the company said.
Gyre plans to present full trial results at a medical congress and file a new drug application with China's National Medical Products Administration in Q3.
In a separate statement, Gyre announced a proposed underwritten public share offering with proceeds to advance its Phase 2 clinical trial of F351 in the US to treat liver fibrosis, among other things.
Gyre shares fell 15% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。